ROS1 translocation is associated with lung cancer.

These data further support functional roles of aberrant ROS1 protein in tumor progression of non-small cell lung carcinoma.

All ROS1 fusion-positive lung tumors lacked alteration of EGFR, KRAS, HER2, ALK, and RET genes.

ROS1 fusion-negative lung cancer patients may have a better survival than ROS1 fusion-positive patients.

ROS1 gene rearrangements are associated with metastatic non--small-cell lung cancer.

Immunohistochemical ROS1 protein expression in lung adenocarcinoma is 100% sensitive and 92% specific for ROS1 rearrangements by fluorescence in situ hybridization.

ROS1 rearrangement is associated with non-small-cell lung cancer.

significance of ROS1 rearrangements in non-small cell lung cancer

These results suggest that co-inhibition of ROS1 and EGFR may be an effective strategy to combat resistance to targeted therapy in some ROS1 fusion-positive non-small cell lung cancer patients.

ROS1 translocations are rare events in resected non-small-cell lung cancers from Caucasian patients

poorer disease-free survival in fusion-positive lung adenocarcinoma patients after curative surgery

ALK, ROS1 and RET fusions are associated with pathological features of lung adenocarcinoma and are more prevalent in solid-predominant adenocarcinoma.

Data show that translocations and amplifications of ROS1 gene occur at a similarly low rate in lung cancer brain metastases as reported for primary tumors

EZR-ROS1 fusion gene is associated with response to therapy in metastatic mediastinum lymph node from a non-small cell lung cancer.

We developed a comprehensive model of acquired resistance to ROS1 inhibitors in non-small cell lung cancer with ROS1 rearrangement and identified cabozantinib as a therapeutic strategy to overcome the resistance.

ROS1 gene copy number gain status is more common in male patients and in cases with squamous histology in non small cell lung cancer

lung cancer featuring a ROS1 rearrangement may be sensitive to protein kinase inhibitor crizotinib

Molecular changes associated with acquired crizotinib resistance in ROS1-rearranged non-small cell lung cancer are heterogeneous, including ROS1 tyrosine kinase mutations, EGFR activation, and epithelial-to-mesenchymal transition.

ROS1 gene rearrangment is associated with drug resistance in non-small-cell lung cancer.

ALK and ROS1 rearrangements found in advanced non-small cell lung cancer patients

lung adenocarcinomas with RET and ROS1 fusions share many radiographic features.

High prevalence of ROS1 copy number alterations are frequent in non-small cell lung cancer.

ROS1-fusion genes act as a driver for the pathogenesis of lung adenocarcinoma.

our study suggested that the prevalence of ALK, ROS1 and RET fusions is very rare in lung squamous cell carcinoma patients.

Durable benefits with pemetrexed-based therapies in RET-rearranged lung cancers are comparable with ALK- and ROS1-rearranged lung cancers. When selecting therapies for patients with RET-rearranged lung cancers, pemetrexed-containing regimens should be considered.

Given the results from the ROS1 cohort of the clinical trial PROFILE 1001, crizotinib represents a new treatment option and the first approved therapy for patients with metastatic non-small cell lung cancer whose tumors are ROS1 positive. Crizotinib demonstrated efficacy irrespective of prior treatment status.

ROS1-positive metastatic lung adenocarcinomas frequently harbor concomitant oncogenic driver mutations.

The frequencies of ALK, ROS1 and RET rearrangements are low in non-adenocarcinoma NSCLC patients. And their clinical characteristics are similar to those in lung adenocarcinoma. Fusions of the above 3 genes are not prognostic factor for non-adnocarcinoma NSCLC patients.

Female, cribriform structure and presence of psammoma body were the three most powerful indicator of ROS1 rearrangement status, and predictive formula was helpful in screening ROS1-rearranged non-small-cell lung carcinomas, especially for ROS1 immunochemistry equivocal cases.

ROS1 mutation is associated with response to chemotherapy in lung adenocarcinoma.

Detection of Gene Rearrangements in Circulating tumor Cells: Examples of ALK-, ROS1-, RET-Rearrangements in Non-Small-Cell lung cancer and ERG-Rearrangements in Prostate cancer.(

in 14 ROS1+ lung adenocarcinoma cases, 9 rearrangements detected (gene partner: CD74 in 8 cases and SLC34A2 in 1)

CEP72-ROS1 is a novel ROS1 fusion variant in non-small cell lung cancer (NSCLC) discovered by next-generation sequencing and could be included in ROS1 detection assay, such as reverse transcription PCR.

Patients with CD74-ROS1 fusion partners are associated with brain metastases in Non-Small Cell lung cancer.

ROS1 gene rearrangement is associated with Non-Small-cell lung cancer.

lung adenocarcinoma in Asian patients aged mutation rate than in those aged >50 years, especially EML4-ALK and ROS1 fusion. mutation analysis may be helpful in determining targeted therapy for the majority of these patients

The upstream breakpoint lies in the same region as the breakpoint of a fused gene SLC34A2-ROS1, which encodes a constitutive kinase in the lung cancer cell line HCC78 and nonsmall-cell lung cancer (NSCLC), suggesting that the deletion in this family is a hot spot for recombination, not only in cancer samples with somatic mutation, but also in PAM patients with germline genetic defects of SLC34A2.

In the largest consecutive routine Asian non-small cell lung cancer (NSCLC) cohort analyzed to date, we found that high PD-L1 expression frequently overlapped with ROS1 rearrangement, while it negatively correlated with EGFR mutations.

ROS1 gene rearrangements are associated with non-small cell lung cancer.

Findings suggest that the measurement of C-terminal ALK or ROS1 protein could be a reliable diagnostic method for each fusion in lung cancer.

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell lung Carcinoma: the ROSING Study.

This is the first study from the Indian subcontinent to identify the frequency of ROS-1 re-arrangements and MET amplification in the Indian lung adenocarcinoma population. c-MET protein expression was identified in 33.33%, and ROS-1 protein expression was detected in 3.33% cases.

Rearrangements of ALK/ROS1 were quantified using circulating tumor cells (CTCs) mRNA and matched with those identified in biopsy specimens from 12 patients with late-stage non-small cell lung cancer. Moreover, CTC counts and copy numbers of ALK/ROS1 rearrangements could be used together for evaluating treatment responses and disease progression.

ROS1-rearranged Non-small-cell lung cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell lung cancer.

Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.

Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.

High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.

High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling pathway in Non-Small Cell lung cancer.

[Clinicopathological significance in non-small cell lung cancer with mutations and co-mutations of EGFR, ALK and ROS1].

Immunocytochemical Detection of ALK and ROS1 Rearrangements in lung cancer Cytological Samples.